Literature DB >> 7171452

The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.

M I Saunders, S Dische, D Fermont, A Bishop, I Lenox-Smith, J G Allen, S L Malcolm.   

Abstract

A new hypoxic cell radiosensitizer, Ro 03-8799, has been administered i.v. to 2 normal and 6 patient volunteers. Generally in non-necrotic tumours the concentrations obtained were 3 times greater than in plasma sampled at the same time. These observations added to the reports concerning toxicology in monkeys and rats and radiosensitizing efficiency in the laboratory, suggest that Ro 03-8799 may prove to be much more effective sensitizer than misonidazole in man.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7171452      PMCID: PMC2011152          DOI: 10.1038/bjc.1982.262

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  4 in total

1.  Neurotoxicity with desmethylmisonidazole.

Authors:  S Dische; M I Saunders; M R Stratford
Journal:  Br J Radiol       Date:  1981-02       Impact factor: 3.039

2.  A serial study of the concentration of misonidazole in human tumors correlated with histologic structure.

Authors:  T A Rich; S Dische; M I Saunders; M R Stratford; A Minchinton
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-02       Impact factor: 7.038

3.  The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.

Authors:  S Dische; M I Saunders; P J Riley; J Hauck; M H Bennett; M R Stratford; A I Minchinton
Journal:  Br J Cancer       Date:  1981-03       Impact factor: 7.640

4.  In vivo assessment of basic 2-nitroimidazole radiosensitizers.

Authors:  M V Williams; J Denekamp; A I Minchinton; M R Stratford
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

  4 in total
  4 in total

1.  Autoradiographic distribution of [14C]-labelled pimonidazole in rhabdomyosarcoma-bearing rats and pigmented mice.

Authors:  F Laurent; P Benard; P Canal; G Soula
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  The pharmacokinetics of a new radiosensitiser, Ro 03-8799 in humans.

Authors:  J G Allen; S Dische; I Lenox-Smith; S L Malcolm; M I Saunders
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  High uptake of RSU 1069 and its analogues melanotic melanomas.

Authors:  J M Walling; J Deacon; S Holliday; I J Stratford
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.

Authors:  G E Adams; I Ahmed; P W Sheldon; I J Stratford
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.